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Abstract
Objective A ‘lite’ version of the EQ-5D-5L valuation protocol, which requires a smaller sample by collecting more data 
from each participant, was proposed and used to develop an EQ-5D-5L value set for Uganda.
Methods Adult respondents from the general Ugandan population were quota sampled based on age and sex. Eligible 
participants were asked to complete 20 composite time trade-off tasks in the tablet-assisted personal interviews using the 
offline EuroQol Portable Valuation Technology software under routine quality control. No discrete choice experiment task 
was administered.
The composite time trade-off data were modelled using four additive and two multiplicative regression models. Model per-
formance was evaluated based on face validity, prediction accuracy in cross-validation and in predicting mild health states. 
The final value set was generated using the best-performing model.
Results A representative sample (N = 545) participated in this study. Responses to composite time trade-off tasks from 492 
participants were included in the primary analysis. All models showed face validity and generated comparable prediction 
accuracy. The Tobit model with constrained intercepts and corrected for heteroscedasticity was considered the preferred 
model for the value set on the basis of better performance. The value set ranges from − 1.116 (state 55555) to 1 (state 11111) 
with ‘pain/discomfort’ as the most important dimension.
Conclusions This is the first EQ-5D-5L valuation study using a ‘lite’ protocol involving composite time trade-off data only. 
Our results suggest its feasibility in resource-constrained settings. The established EQ-5D-5L value set for Uganda is expected 
to be used for economic evaluations and decision making in Uganda and the East Africa region.
Key Points 
This is the first EQ-5D-5L valuation study using a ‘lite’ 
protocol, which requires a smaller sample by collecting 
more composite time trade-off data from each respond-
ent.
This is the first EQ-5D-5L value set in Uganda, the sec-
ond in East Africa (following Ethiopia) and the third in 
Africa (following Ethiopia and Egypt).
The value set is expected to serve as the foundation for 
sound health economic evaluations and health technol-
ogy assessment to inform decision making in the health-
care system in Uganda and the East Africa region.
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work as first authors.
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1 Introduction
The EQ-5D family of instruments has been widely used 
around the world as a measure of health outcomes to 
inform resource allocation and decision making. The 
EQ-5D covers five dimensions of health (mobility, self-
care, usual activities, pain/discomfort and anxiety/depres-
sion). The newer version (EQ-5D-5L) has five response 
levels for each dimension (no problems, slight problems, 
moderate problems, severe problems, unable/extreme 
problems). Empirical evidence has demonstrated the supe-
riority of EQ-5D-5L over the earlier version (EQ-5D-3L) 
in terms of measurement properties, such as reduced 
ceiling effects and greater discrimination among known 
groups [1–4].
The value set accompanying EQ-5D represents the 
preferences of the general population of a country/region 
for health states defined by EQ-5D. It generates prefer-
ence-based health-related quality-of-life scores on a scale 
anchored at 1 (full health) and 0 (dead), which allows qual-
ity-adjusted life-year (QALY) calculations, often used in 
economic evaluations. The EuroQol group developed a 
standardised valuation study protocol, the EuroQol Valu-
ation Technology (EQ-VT), to create value sets for the 
EQ-5D-5L [5]. Following this protocol, EQ-5D-5L value 
sets have been developed in several countries, mainly in 
Asia [6–11], Europe [12–17], North America [18–20] and 
South America [21, 22].
In African countries, methods of health technology 
assessment (HTA) including economic evaluations have 
been increasingly used to inform the allocation of scarce 
healthcare resources [23, 24]. However, in this region, one 
EQ-5D-3L value set for Zimbabwe [25] was developed 
in the early 2000s before the availability of the stand-
ardised protocol and one EQ-5D-3L value set for Tuni-
sia was published in 2021 [26]. One EQ-5D-5L value set 
for Ethiopia became available in 2020 [27] and that for 
Egypt is expected to be published soon. Consequently, 
most health economic and clinical research conducted in 
this region using EQ-5D instruments have had to rely on 
value sets derived in other countries. The EQ-5D value 
set reflects the social preferences of a population, which 
differs between countries. Therefore, a country-specific 
EQ-5D-5L value set, developed using the standardised 
protocol, is preferred and would provide valuable informa-
tion to inform future economic evaluations of healthcare 
interventions and policies in a context where better deci-
sions regarding resource allocation are essential.
The EQ-VT protocol includes composite time trade-
off (cTTO) and discrete choice experiment (DCE) tasks 
[28]. The cTTO task is an iterative procedure in which 
respondents choose between living in a certain impaired 
health state for 10 years, or in full health for a smaller or 
equal number of years. The years in full health are then 
varied until the respondent indicates they are indifferent 
between the two alternatives. The DCE requires respond-
ents to compare two health states and indicate which one 
is better. These tasks could be cognitively burdensome 
and obtaining the recommended sample size of 1000 
respondents from the general population is resource inten-
sive. Given these considerations, there have been some 
attempts to develop lighter versions of a valuation protocol 
that require fewer resources or are potentially easier to 
implement [29]. In the recently available EQ-5D-5L value 
set for Peru [22], the authors explored the feasibility of 
a protocol using DCE data; however, the results suggest 
substantial differences between cTTO-derived and DCE-
derived values.
Taking all information into consideration, we proposed 
a ‘lite’ valuation protocol, which requires a reduced sample 
size by collecting more cTTO data from each respondent. 
The valuation study was undertaken in Uganda, one of the 
major focuses of clinical trial research for low-to-middle 
income countries, specialising particularly, though not only, 
in human immunodeficiency virus research [30–32]. The 
availability of a value set would promote the use of the EQ-
5D-5L tool in trials to measure and quantify health benefits. 
Health economic evidence is used by the Uganda Ministry of 
Health to guide decision making, including decisions relat-
ing to Uganda’s Essential Package of Health Services [33]. 
Therefore, in this study, we aimed to develop the EQ-5D-5L 
value set for Uganda using this ‘lite’ valuation protocol.
2  Methods
The EuroQol Portable Valuation Technology (EQ-PVT) 
software, a portable version of EQ-VT, which collects data 
using an offline tool in macro-enabled Microsoft Power-
Point, was adapted to accommodate the design of this ‘lite’ 
version.
2.1  Valuation Technique
Considering the good psychometric properties of time trade-
off (TTO) in evaluating health states in Ugandan individuals 
[34], cTTO was used in this study. In cTTO tasks, for each 
health state to be valued, respondents are first asked their 
preference between living in full health for 10 years and 
living in this state for 10 years. The length of time lived 
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in full health is varied until the two options are considered 
indifferent. When the respondents indicate that they would 
rather die (0 years in full health) than have to live in a health 
state for 10 years, this state is considered ‘worse than dead’ 
and the respondents move into the lead time TTO (LT-TTO), 
in which they are asked to choose between 10 years of full 
health in life A, and 10 years of full health in life B followed 
by 10 years in the health state that is valued. The number 
of life-years in life A is then subsequently varied (but equal 
or lower than 10) until reaching the point of indifference. 
Thus, the cTTO values range from − 1 to 1. The time traded 
is altered in units of 0.5 years.
2.2  Health States
The EQ-VT [28] design selected a subset of 86 from the 
3125  (55) health states defined by EQ-5D-5L dimensions 
and response levels to represent a wide range of health prob-
lems, divided into ten blocks of ten health states. All ten 
blocks included the worst state (55555), one state with mild 
problems in one dimension only, and eight states unique to 
each block that varied in severity. The standard valuation 
approach is 1000 respondents each valuing ten health states.
We adapted the EQ-VT design to allow 20 health states 
to be valued by each respondent from a smaller sample (N = 
500). This resulted in the same number of cTTO responses 
as the standard valuation approach (500 respondents × 20 
tasks = 1000 respondents × 10 tasks). Each of the ten blocks 
of ten health states was combined with its adjacent block to 
form ten new blocks, i.e. 1 and 2, 2 and 3, 3 and 4, 4 and 5, 
5 and 6, 6 and 7, 7 and 8, 8 and 9, 9 and 10, 10 and 1. The 
repeated health state 55555 in each block was replaced with 
one of the five severe health sates (45555, 54555, 55455, 
55545, 55554). These newly formed ten blocks of health 
states included 91 health states, with 20 health states per 
block. Each participant was randomly assigned to one of 
the ten blocks.
2.3  Sampling and Recruitment
Uganda is a culturally and linguistically diverse country with 
ten main languages. Using multiple languages was logisti-
cally impossible and might negatively affect data quality. 
We therefore decided to collect data from the Central region 
using Luganda (the most widely spoken language in this 
region), covering approximately 30% of the Ugandan general 
population [35]. Data were collected between March and 
May 2021 from four districts (Mubende, Masaka, Kampala 
and Wakiso) of the Central region, including both rural and 
urban residents. The total target sample size was 500 and 
in each district, quotas were set at 125 participants whose 
characteristics in age and sex resembled those of the general 
population in Uganda [35].
To enable interviewers to focus on the valuation tasks, we 
recruited two research assistants as field mobilisers to help 
with participant recruitment. The field mobilisation, includ-
ing area selection, local council communication and partici-
pant identification, was conducted prior to the data collec-
tion in each district. Adults who were able to understand the 
cTTO tasks (as judged by the mobilisers and interviewers) 
were eligible to participate. Each respondent received Ugan-
dan Shilling 25,000 (US$7) to compensate for the time and 
travel expenses.
2.4  Survey Administration
Informed written consent was sought and granted before the 
interview. All surveys were completed through interviewer-
assisted data collection using Windows-based tablets with 
the EQ-PVT in Luganda. First, participants were asked to 
provide information about demographic characteristics (age, 
sex, education, ethnicity and religion). Second, they reported 
their current level of health as described by the EQ-5D-5L 
(including EQ-5D descriptive system and EQ visual ana-
logue scale). Third, participants completed the cTTO valu-
ation tasks, as instructed by the interviewers, including the 
wheelchair example (three states: wheelchair, better than 
wheelchair and worse than wheelchair), three practice health 
states (21121, 35554 and 15411) and 20 health states. Last, 
they answered questions about their socioeconomic status 
(including marriage, employment and income), health condi-
tions (e.g. illness) and understanding of health (e.g. which 
EQ-5D dimension is most/least important to health).
2.5  Interviewer Training and Quality Control
Following the EQ-VT guideline that each interviewer is 
expected to complete 80–100 interviews, we recruited six 
interviewers. They, together with the two field mobilisers, 
received face-to-face, a full-week training before the field-
work, delivered by the lead health economists who were 
trained by EuroQol using EQ-VT [28]. The training included 
lectures about valuation methodology, practices and mock 
interviews. Data from mock interviews (two from each inter-
viewer) were checked for quality and individual and group 
feedback was provided to all interviewers. The same six 
interviewers were involved throughout data collection in all 
four districts. During data collection, completed interviews 
were stored on the tablets and then uploaded to a secure 
shared drive when Internet links were available and checked 
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for quality daily. Data collected in the first two days were 
treated as ‘practice data’ with each interviewer completing 
at least six interviews. One lead health economist was travel-
ling together with fieldworkers to supervise data collection 
and provide feedback according to quality check reports.
The quality of cTTO data was checked based on several 
criteria [36]. These criteria include protocol compliance 
indicators such as time spent on the wheelchair example dur-
ing which the cTTO task is explained to the respondent (≥ 3 
minutes) and time spent on cTTO tasks (≥ 10 minutes for all 
20 tasks), whether the interviewers explained the lead-time 
part of the cTTO exercise, whether state 55555 received 
the lowest value, and whether a logically better state has a 
value 0.5 lower or more than the worse state (severe incon-
sistency). Data from participants who had severe inconsist-
ency in responses were excluded from the primary analysis. 
Furthermore, the data were checked for interviewer effects, 
in which the proportion of worse than death responses, the 
proportion of responses assigned to various values (− 1, 0 
and 1) and the general distribution of responses were com-
pared between interviewers.
2.6  Data Analysis
2.6.1  Model Construction
One previous study comparing different modelling meth-
ods for EQ-5D-5L value sets concluded that a model with 
parameters for all dimensions and levels performed best 
[37]. Some issues relevant to the cTTO data also need to 
be considered. First, the cTTO data are left censored at − 1 
because respondents could hypothetically continue trading 
more time in full health for ‘worse than dead’ health states 
than possible in the cTTO task, which would result in a value 
beyond the lower bound − 1. Second, heteroskedasticity may 
exist as the cTTO values for the mild health states could be 
in a relative smaller range while the range of values for the 
more severe health states could be much larger. As a result, 
the bias in the valuation of severe states tends to be higher 
than in the valuation of mild states [37]. Third, the EQ-VT 
design allows only 41 distinct cTTO values, ranging from 
− 1 to 1 with steps of 0.05 [36]. Therefore, the following 
regression models were tested.
Model 1 is an additive 20-parameter linear regression 
model. The 20 parameters (4 levels × 5 dimensions) represent 
the value decrement assigned to the level-dimension combina-
tions of EQ-5D-5L health states, with level 1 (no problems) 
as the baseline (Eq. 1). α represents the intercept, ε the error 
term and μ the respondent-level random intercept. Model 2 
is an additive 20-parameter Tobit model, accommodating the 
left-censored nature of cTTO data. The Tobit model assumes 
a latent variable (cTTO*) underlying the observed cTTO val-
ues. The latent variable (cTTO*) can take on values beyond 
the range of the observed values censored at − 1. The Tobit 
model uses a likelihood function to adjust the parameter 
estimates for the probability of the latent preferences being 
beyond the censored value, that is, if cTTO* ≤ − 1, observed 
cTTO = − 1 and if cTTO* > − 1, observed cTTO = cTTO*:
The two models were further corrected for heteroskedas-
ticity, resulting in models 3 and 4, respectively. These two 
models were also estimated with constraining the intercept, 
i.e. α = 1, forcing the predicted value for state 11111 to be 1.
Multiplicative models have also been used for produc-
ing value sets, for example, the EQ-5D-5L value set for 
China [6]. Thus, we included two multiplicative models 
as candidates. Model 5 includes eight parameters, with 
five parameters representing the value decrement of having 
level 5 problems on each dimension (βMO, βSC, βUA, βPD, 
βAD) and three parameters for levels 2, 3 and 4 problems 
(L2, L3, L4) (Eq. 2). This will result in the value decrement 
of having level 2/3/4 problems as the product of value 
decrement of having level 5 problems multiplied by level, 
for example, level 3 in mobility is βMO × L3:
Model 6 is an extension to model 5, including nine 
parameters, in which one additional parameter (L5) is 
used to distinguish level 5 in pain/discomfort and anxiety/
depression dimensions (‘extreme’) to level 5 in mobility, 
self‐care and usual activity dimensions (‘unable’) (Eq. 3). 
Thus, the value decrement of having level 5 problems in 
the five dimensions would be βMO, βSC, βUA, βPD × L5, βAD 
× L5. Models 5 and 6 were estimated with constrained 
intercepts:
(1)
Health-related quality of life values
=  + MO2MO2 + SC2SC2 + UA2UA2 + PD2PD2 + AD2AD2
+ MO3MO3 + SC3SC3 + UA3UA3 + PD3PD3 + AD3AD3
+ MO4MO4 + SC4SC4 + UA4UA4 + PD4PD4 + AD4AD4
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2.6.2  Model Evaluation
We set some criteria to select the preferred model. The 
first criterion was the face validity, for which the model 
should generate logically consistent parameter estimates 
(i.e. a larger decrement with more severe problems). The 
second criterion was the prediction accuracy of models in 
predicting values for health states. A leave-out-by-state 
cross-validation method was used by excluding each health 
state in turn from estimating model coefficients and then 
calculating the predicted values for the left-out state using 
the fitted model. Similarly, a leave-out-by-block cross-val-
idation was conducted by excluding one block of health 
states to estimate model coefficients and to predict values 
for the states in the left-out block. We also examined the 
prediction accuracy for 11 mild health states (level 1/2 in 
maximum 2 dimensions), such as state 11122. Two types 
of prediction errors, mean absolute error (MAE) and root 
mean squared error (RMSE), were calculated using the 
predicted and observed mean values for health states, 
with lower MAE/RMSE being favoured. In the event of 
inconsistent results in the comparison, we looked at the 
absolute values in the MAE/RMSE to assist in selecting 
the preferred model.
2.6.3  Model Estimation
The best-performing model was used to develop the value 
set. The following sensitivity analyses were conducted to 
evaluate the robustness of the primary analysis:
a. Re-inclusion of data from respondents who had severe 
inconsistency in responses (i.e. full sample),
b. Exclusion of data from each interviewer in turn to exam-
ine interviewer effects.
In the analysis, we used rescaled cTTO values (1-cTTO 
values), which results in the values on a scale between 0 and 
2, the intercept suppressed to 0, and parameter estimates 
being positive, for easier comparison between models. All 
analyses were conducted using Stata 16.1 (StataCorp LLC). 
The command intreg was used for models 3 and 4 and the 
command menl for models 5 and 6.
3  Results
3.1  Participants’ Characteristics
In total, 545 participants were recruited with complete data. 
Responses from 53 (7.7%) participants were flagged as hav-
ing severe inconsistency, and their responses were excluded 
from the primary analysis, resulting in a sample of 492 par-
ticipants. The full sample and analytic sample were gener-
ally representative of the Ugandan adult population in terms 
of age and sex (Table 1), although the education level was 
higher and there were more participants of the Baganda eth-
nic group. Self-reported health using EQ-5D-5L showed that 
the proportions of reported problems varied from 2.6% in 
self-care to 47.8% in pain/discomfort, while 179 (36.4%) 
respondents reported no problems in any dimension (11111) 
(Table 1).
3.2  cTTO Data
Respondents in the analytic sample took an average of 8.9 
± 5.3 iterative steps before reaching the point of indiffer-
ence. Mean time spent on 20 tasks was 30.1 ± 10.9 min-
utes. The main analysis included 9840 cTTO responses from 
492 participants (492 × 20 = 9840), of which 4361 (44.3%) 
were negative (Fig. 1a). The proportion of values clustered 
at − 1, 0 and 1 was 2.32%, 2.27% and 4.97%, respectively. 
The higher the severity level (i.e. sum of levels across 
dimensions), the lower the mean cTTO value (Fig. 1b). The 
observed mean cTTO value ranged from − 0.844 for state 
55555 to 0.960 for state 11112 [Table S1 of the Electronic 
Supplementary Material (ESM)].
3.3  Models
All models showed face validity with a larger value decre-
ment for more severe problems (Table 2). Regarding pre-
diction accuracy, model 5 generated the smallest MAE and 
RMSE in leave-out-by-state cross-validation and model 2 
with unconstrained intercepts generated the smallest MAE 
and RMSE in leave-out-by-block cross-validation, but other 
models displayed very similar MAE/RMSE (Table 3). When 
predicting values for mild health states, model 4 with con-
strained intercepts performed the best with much smaller 
MAE and RMSE than other models. Thus, model 4 with 
constrained intercepts was considered the best-performing 
model.
3.4  Value Set
The final EQ-5D-5L value set was developed using model 
4 with constrained intercepts (Table 4). The largest value 
decrement for a dimension level was pain/discomfort level 
5 (0.798) and the smallest was anxiety/depression level 2 
(0.050). The relative importance of dimensions was pain/
discomfort (most important), mobility, self-care, usual activ-
ity and anxiety/depression (least important) (Table 4).
When applying this scoring algorithm to EQ-5D-5L 
responses, a health-related quality-of-life value is 
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Table 1  Demographics of the participants in the Ugandan valuation study
General population (%) Full sample (N = 545) Analytic  samplea (N = 492)
Setting, n (%)
 Urban 277 (50.8) 252 (51.2)
 Rural 268 (49.2) 240 (48.8)
Age (years), mean ± SD 38.4 ± 13.8 38.6 ± 14.0
Age groups, n (%)
 Young (18–34) 55 252 (46.2) 226 (45.9)
 Middle-aged (35–59) 35 241 (44.2) 218 (44.3)
 Old (60 and above) 10 52 (9.5) 48 (9.8)
Sex, n (%)
 Female 51 292 (53.6) 263 (53.5)
 Male 49 253 (46.4) 229 (46.5)
Education, n (%)
 Primary or lower 71 274 (50.3) 247 (50.2)
 Secondary 23 197 (36.2) 175 (35.6)
 Higher than secondary 6 74 (13.6) 70 (14.2)
Ethnicity, n (%)
 Baganda 17 315 (57.8) 281 (57.1)
 Banyankore 11 50 (9.2) 47 (9.6)
 Bakiga/Basoga 14 37 (6.8) 35 (7.1)
Others 58 143 (26.2) 129 (26.2)
 Religion, n (%)
 Christian 53 302 (55.4) 267 (54.3)
 Anglican 32 136 (25.0) 126 (25.6)
 Muslim and others 16 107 (19.6) 99 (20.1)
Marital status, n (%)
 Married/co-habiting 307 (56.3) 273 (55.5)
 Single 134 (24.6) 121 (24.6)
 Divorced/widowed 104 (19.1) 98 (19.9)
Employment status, n (%)
 Employed 439 (80.7) 396 (80.7)
 Unemployed 59 (10.9) 56 (11.4)
 Others 46 (8.5) 39 (7.9)
Income level, n (%)
 ≤400K 402 (74.3) 364 (74.4)
 400K–1850K 113 (20.9) 102 (20.9)
 >1850K 26 (4.8) 23 (4.7)
Household, mean ± SD
 No. of adults 2.5 ± 1.8 2.6 ± 1.9
 No. of children 2.8 ± 2.1 2.8 ± 2.2
 Overall health, n (%)
 Excellent 56 (10.3) 51 (10.4)
 Good 312 (57.4) 279 (56.8)
 Fair 161 (29.6) 147 (29.9)
 Poor/very poor 15 (2.8) 14 (2.9)
Illness, n (%)
 Yes 151 (27.8) 138 (28.1)
Health insurance, n (%)
 Yes 41 (7.5) 38 (7.7)
EQ-5D-5L mobility, n (%)
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obtained by subtracting parameter estimates for each 
dimension level of the health state from 1 (see Appendix 
in the ESM for Stata codes). For example, for the health 
state 23514, the value would be 1 − (0.073 + 0.110 + 
0.306 + 0 + 0.235) = 0.276. The predicted EQ-5D-5L 
values ranged from − 1.116 (for state 55555) to 1. Fig-
ure 2 displays the scatterplots of observed TTO values 
against predicted values for the 91 health states included 
in this study. The mean value using this value for the 
study sample was 0.863 ± 0.196 and the distribution was 
shown in Fig. 3.
3.5  Sensitivity Analysis
Using the full sample, all models demonstrated face validity 
(Table S3 of the ESM); model 2 with unconstrained intercepts 
generated the smallest MAE and RMSE in cross-validation 
analyses and model 4 with constrained intercepts performed 
the best in predicting mild states (Table S4 of the ESM). After 
looking at the absolute values in MAE/RMSE, model 4 with 
constrained intercepts was the preferred model, consistent with 
the main analysis. The model parameter estimates using the ana-
lytic sample and the full sample were almost identical (Table 4).
Table 1  (continued)
General population (%) Full sample (N = 545) Analytic  samplea (N = 492)
 No problems 438 (80.4) 396 (80.5)
 Slight problems 71 (13.0) 63 (12.8)
 Moderate problems 31 (5.7) 28 (5.7)
 Severe problems 5 (0.9) 5 (1.0)
 Unable to walk about 0 – 0 –
EQ-5D-5L self-care, n (%)
 No problems 530 (97.3) 479 (97.4)
 Slight problems 9 (1.7) 7 (1.4)
 Moderate problems 5 (0.9) 5 (1.0)
 Severe problems 1 (0.2) 1 (0.2)
 Unable to wash or dress 0 – 0 –
EQ-5D-5L usual activities, n (%)
 No problems 433 (79.5) 389 (79.1)
 Slight problems 73 (13.4) 68 (13.8)
 Moderate problems 29 (5.3) 26 (5.3)
 Severe problems 10 (1.8) 9 (1.8)
 Unable to do usual activities 0 – 0 –
EQ-5D-5L pain/discomfort, n (%)
 No pain/discomfort 282 (51.7) 257 (52.2)
 Slight pain/discomfort 166 (30.5) 148 (30.1)
 Moderate pain/discomfort 78 (14.3) 71 (14.4)
 Severe pain/discomfort 19 (3.5) 16 (3.3)
 Extreme pain/discomfort 0 – 0 –
EQ-5D-5L anxiety/depression, n (%)
 Not anxiety/depression 327 (60.0) 293 (59.6)
 Slightly anxiety/depression 154 (28.3) 140 (28.5)
 Moderately anxiety/depression 40 (7.3) 39 (7.9)
 Severely anxiety/depression 23 (4.2) 20 (4.1)
 Extremely anxiety/depression 1 (0.2) 0 –
EQ-5D-5L state, n (%)
 11111 195 (35.8) 179 (36.4)
 Any other health state 350 (64.2) 313 (63.6)
 EQ visual analogue scale, mean ± SD 76.1 ± 15.6 75.9 ± 15.8
SD standard deviation
a Excluding participants who had severe inconsistency in responses
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The parameters of the best-performing model were re-
estimated using data excluding each interviewer in turn. 
The differences in model parameter estimates were marginal 
(Table S5 of the ESM).
4  Discussion
In this study, for the first time, we used a ‘lite’ protocol 
that collected more cTTO data from half of the sample 
Fig. 1  Distribution of composite time trade-off (cTTO) observations by (a) value and (b) health state severity. Misery score is calculated by 
summing the severity levels across all five dimensions; for example, the misery score for health state 23514 would be 15 (2+3+5+1+4)
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Table 2  Parameter estimates of the fitted models using the analytic sample (N = 492)
a Parameters transformed in 20-parameter form for comparison purposes
* p = 0.105; **p = 0.092; other p values are <0.01







Model 3, linear (corrected 
for heteroskedasticity)






Unconstrained Unconstrained Unconstrained Constrained Unconstrained Constrained Constrained Constrained
MO2 0.096 0.093 0.073 0.079 0.066 0.073 0.061 0.062
MO3 0.154 0.146 0.171 0.174 0.143 0.146 0.102 0.103
MO4 0.255 0.246 0.257 0.260 0.242 0.245 0.287 0.289
MO5 0.386 0.390 0.358 0.359 0.375 0.376 0.345 0.344
SC2 0.035 0.035 0.067 0.075 0.061 0.068 0.058 0.059
SC3 0.113 0.111 0.116 0.115 0.111 0.110 0.097 0.097
SC4 0.251 0.248 0.244 0.245 0.238 0.240 0.271 0.274
SC5 0.310 0.324 0.324 0.325 0.353 0.354 0.327 0.326
UA2 0.033 0.032 0.053 0.061 0.051 0.060 0.055 0.056
UA3 0.065 0.066 0.075 0.079 0.077 0.081 0.092 0.092
UA4 0.223 0.222 0.242 0.247 0.238 0.243 0.257 0.259
UA5 0.270 0.284 0.268 0.270 0.304 0.306 0.310 0.308
PD2 0.087 0.084 0.080 0.087 0.076 0.082 0.129 0.128
PD3 0.133 0.131 0.149 0.149 0.139 0.138 0.214 0.213
PD4 0.563 0.564 0.583 0.582 0.582 0.580 0.600 0.598
PD5 0.680 0.693 0.781 0.786 0.793 0.798 0.723 0.725
AD2 0.029 0.029 0.044 0.052 0.043 0.050 0.045 0.045
AD3 0.134 0.131 0.132 0.138 0.121 0.127 0.075 0.075
AD4 0.222 0.221 0.237 0.241 0.231 0.235 0.212 0.211
AD5 0.255 0.262 0.257 0.260 0.279 0.282 0.255 0.256
Constant 0.046 0.045 0.013* – 0.013** – – –
Table 3  Prediction accuracy of models using the analytic sample (N = 492)
Bold values indicate the smallest MAE/RMSE
MAE mean absolute error, RMSE root mean squared error







Model 3, linear (corrected 
for heteroskedasticity)






Unconstrained Unconstrained Unconstrained Constrained Unconstrained Constrained Constrained Constrained
Cross-validation: leave-out by state
 MAE 0.086 0.084 0.092 0.091 0.087 0.086 0.081 0.082
 RMSE 0.114 0.110 0.122 0.122 0.120 0.120 0.109 0.110
Cross-validation: leave-out by block
 MAE 0.074 0.073 0.077 0.078 0.074 0.075 0.076 0.077
 RMSE 0.098 0.095 0.101 0.102 0.102 0.103 0.102 0.103
Predicting mild states
 MAE 0.032 0.029 0.015 0.014 0.011 0.010 0.020 0.019
 RMSE 0.041 0.038 0.017 0.016 0.012 0.011 0.028 0.028
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size recommended in the standard protocol. Our results 
provide evidence of the successful completion of this pro-
tocol, combined with intensive interviewer training and 
data monitoring. The value set generated would be the first 
EQ-5D-5L value set in Uganda, the second in East Africa 
(following Ethiopia [27]) and the third in Africa (follow-
ing Ethiopia [27] and Egypt).
The design of this ‘lite’ protocol that collected more 
cTTO data from fewer participants was informed by find-
ings from existing studies. A substantial number of pub-
lished EQ-5D-5L value sets are based on cTTO data only, 
such as Canada [18], China [6], the Netherlands [12], 
Japan [8], Korea [9], Uruguay [21] and, more recently, 
the USA [19], Peru [22], Hungary [17] and Mexico [20], 
enhancing the acceptability of using cTTO data in devel-
oping value sets. The attempt to rely on DCE data in a 
Peruvian valuation study [22] resulted in marked differ-
ences in parameter estimates using DCE only and using 
cTTO only, potentially casting doubt on the protocol that 
is less reliant on cTTO. The valuation technique, TTO, 
has been reported to have good psychometric properties 
among Ugandan individuals [34], making it possible to 
explore this ‘lite’ design in Uganda. Given the results 
observed in this study, this ‘lite’ protocol has the potential 
to be used widely, especially in low-income and middle-
income countries. Therefore, we highly recommend future 
EQ-5D-5L valuation studies consider this protocol and the 
evidence generated would advance the understanding of 
Table 4  Parameter estimates of 
the value set using the analytic 
sample (N = 492) and using the 
full sample (N = 545)
Model 4, Tobit (with constrained intercepts, corrected for heteroskedasticity)
Analytic sample (N = 492) Full sample (N = 545)
Coefficient Standard error p value Coefficient Standard error p value
MO2 0.073 0.008 0.000 0.075 0.008 0.000
MO3 0.146 0.014 0.000 0.144 0.013 0.000
MO4 0.245 0.013 0.000 0.243 0.012 0.000
MO5 0.376 0.012 0.000 0.376 0.012 0.000
SC2 0.068 0.007 0.000 0.071 0.007 0.000
SC3 0.110 0.012 0.000 0.121 0.012 0.000
SC4 0.240 0.012 0.000 0.239 0.012 0.000
SC5 0.354 0.012 0.000 0.346 0.011 0.000
UA2 0.060 0.006 0.000 0.064 0.007 0.000
UA3 0.081 0.012 0.000 0.075 0.011 0.000
UA4 0.243 0.011 0.000 0.247 0.011 0.000
UA5 0.306 0.012 0.000 0.290 0.012 0.000
PD2 0.082 0.006 0.000 0.090 0.006 0.000
PD3 0.138 0.014 0.000 0.139 0.013 0.000
PD4 0.580 0.012 0.000 0.570 0.012 0.000
PD5 0.798 0.013 0.000 0.788 0.012 0.000
AD2 0.050 0.006 0.000 0.057 0.006 0.000
AD3 0.127 0.012 0.000 0.140 0.012 0.000
AD4 0.235 0.012 0.000 0.241 0.011 0.000
AD5 0.282 0.011 0.000 0.281 0.011 0.000
Fig. 2  Predicted values vs observed values for all the health states 
valued in this study
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valuation study design, contributing to the wide use of 
EQ-5D-5L in measuring health outcomes.
Based on the pre-specified criteria, the Tobit model with 
constrained intercepts, corrected for heteroskedasticity, was 
the preferred model for generating the value set. In cross-
validation analyses, all models showed similar MAE/RMSE 
while the multiplicative model 5 had the lowest MAE/RMSE 
in leave-out-by-state cross-validation. The multiplicative 
models make a very strong assumption on the structure 
of the EQ-5D-5L dimensions and levels, which was not 
reflected in other models that were able to identify coeffi-
cients for all 20 parameters independently. We also consid-
ered the intercept of the models, which indicates the high-
est value that the model could predict (for state 11111). A 
previous study highlighted that allowing a large gap between 
the predicted value for state 11111 and 1 (full health) could 
result in over-investment in treatments for very mild health 
problems as the intended use of value sets is used to inform 
priority decisions [6]; thus, we suppressed the intercept in 
regression models of rescaled values (1-cTTO) to be 0. This 
approach was further supported by the finding that inter-
cepts in models 3 and 4 (unconstrained) were not statistically 
significant (Table 2). Taking the exact MAE/RMSE values 
into account, model 4 with constrained intercepts displayed 
better precision in predicting mild states and the same level 
of precision in cross-validation as other models, thus it was 
considered the preferred model.
The final EQ-5D-5L value set for Uganda suggests that 
pain/discomfort is the most important dimension while 
anxiety/depression the least. These results were in line with 
the responses from participants who were directly asked 
“which dimension is most/least important relating to your 
health?” (Table S6 of the ESM), supporting the validity of 
the value set. Compared to other countries, pain/discom-
fort was considered the most important in the USA [19] and 
Germany [14] and the second most important in Ethiopia 
[27]. Interestingly, the least important dimension observed 
here, anxiety/depression, was rated the most important in 
Ethiopia [27]. This might be explained by cultural factors. 
The Luganda translation for ‘anxiety/depression’ (okweral-
iikirira/okwenyamira) is not a native concept to the Ugandan 
cultures where mental health is less focused. It is generally 
taboo (traditionally) and considered a weakness for someone 
to show signs of mental illness or even the need for mental 
healthcare. Thus, it is unsurprising that the mental health 
is rated least, consistent with findings observed in previous 
research [38].
The value set generates the maximum predicted value 
(except full health) at 0.950 for state 11112 and the mini-
mum value at − 1.116 for state 55555. Compared to the 
Ethiopia value set [27] with a range from − 0.718 to 0.974 
(state 11112), the extreme health states had lower values in 
Uganda. Additionally, the state 55555 in Uganda at − 1.116 
was below the lower bound of the value sets that are cur-
rently available. These differences may result from the sub-
stantial differences in health preference across populations, 
but the fact that the data were collected during the global 
COVID-19 pandemic (March–May 2021) may also contrib-
ute. Future research would be valuable to explore the impact 
of the pandemic on health valuations.
The study’s limitations should be noted. Mainly, there 
may be issues with the sample’s representativeness. The 
higher education level in our sample was most likely 
because of the fact that people of lower education may have 
Fig. 3  Distribution of EQ-
5D-5L values of the analytic 
sample (N = 492)
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difficulties understanding the cTTO tasks. The ethnicity 
distribution may result from the data having been collected 
in the Central region where more people of the Baganda 
ethnic group live [35]. In addition to considering different 
languages used across regions, collecting data from the Cen-
tral region was a pragmatic approach given the COVID-19 
pandemic internationally and the travel restrictions imple-
mented locally. Despite these issues, our findings were 
consistent with existing value sets for other countries and 
previous research in Uganda, backing our recommendation 
that this value set is appropriate for application in HTA and 
economic evaluations throughout Uganda.
5  Conclusions
This is the first EQ-5D-5L valuation study using a ‘lite’ 
protocol involving cTTO data only. Our results support its 
feasibility, which could benefit future valuation studies, 
especially in resource-constrained settings.
This study established the EQ-5D-5L value set for 
Uganda. We expect it to serve as the foundation for sound 
health economic evaluations and HTA to inform decision 
making in the healthcare system in Uganda and the East 
Africa region.
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